Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin

Cisplatin is an effective chemotherapeutic agent for treating triple negative breast cancer (TNBC). Nevertheless, cisplatin-resistance might develop during the course of treatment, allegedly by metabolic reprograming, which might influence epigenetic regulation. We hypothesized that the histone deac...

Descripción completa

Detalles Bibliográficos
Autores principales: Granit, Avital, Mishra, Kumudesh, Barasch, Dinorah, Peretz-Yablonsky, Tamar, Eyal, Sara, Kakhlon, Or
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760697/
https://www.ncbi.nlm.nih.gov/pubmed/36544904
http://dx.doi.org/10.3389/fcell.2022.1014798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760697/
https://www.ncbi.nlm.nih.gov/pubmed/36544904
http://dx.doi.org/10.3389/fcell.2022.1014798

Ejemplares similares